Study shows safety, efficacy of drug-eluting contact lens for glaucoma
Click Here to Manage Email Alerts
MediPrint Ophthalmic announced that the SIGHT-1 clinical trial found a favorable safety and tolerability profile and demonstrated single dose efficacy of the LLT-BMT1 drug-eluting contact lens to treat mild to moderate glaucoma or ocular hypertension.
“I was excited to study this investigational treatment and believe that LLT-BMT1’s unique product presentation and potential benefits differentiate it from other glaucoma treatments currently on the market,” David Wirta, MD, medical director of the Eye Research Foundation and principal investigator of the study, said in a press release from the company.
According to the release, the Sustained Innovative Glaucoma and ocular Hypertension Treatment (SIGHT) study enrolled five patients naive to contact lens wear who wore the LLT-BMT1 lens imprinted with bimatoprost for 7 days. The patients, whose average age was 77.4 years old, demonstrated 100% tolerability and no significant adverse events.
The company said in the release that the study also indicated efficacy from a single dose, which was not a planned endpoint of the study design.
“However, this indicator encourages the company to proceed swiftly with SIGHT-2, a phase 2b dose-ranging clinical study intended to optimize dosage for efficacy,” the company said.
“We are encouraged by the results of the SIGHT-1 study because they validated the MediPrint process and contact lenses for treating human subjects, allowing our company to advance a number of assets in our pipeline to help protect sight for patients suffering from conceivably disabling eye diseases like glaucoma,” Dan Meyers, CEO of MediPrint Ophthalmics, said in the release.